SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Suven Life Sciences plans to raise funds for clinical trials

Suven Life Sciences Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 530239 | NSE: SUVEN

18 Nov 2009 Evaluate

Suven Life Sciences Ltd, the Hyderabad-based biopharmaceutical company is working on 10 new molecules for central nervous system (CNS) disorders or ailments, plans to raise funds for further trials on one of these, SUVN-502 that is intended for the symptomatic treatment of Alzheimer’s disease, schizophrenia and other disorders of memory and cognition such as attention deficiency and hyperactivity disorder and Parkinson’s disease. CNS disorders account for around 35% of the total disease burden in the world’s seven largest pharmaceutical markets with sales estimated at over $100 billion (Rs4.63 trillion) out of the total global pharmaceutical market sales of $780 billion. The molecule, first-in-class, has successfully completed phase-I studies in Switzerland with promising results. It is now undergoing bridge toxicological studies prior to the initiation of proof of concept or phase-IIa trials on patients.

Suven is targeting a commercial launch of the drug in late 2013 or early 2014 for this the company needs around $20 million to fund the phase-IIa studies. The company has initiated talks with some global pharmaceutical firms to out-license the molecule. However, it is not confident of attractive upfront or milestone payments when the drug candidate is out-licensed before the tier-IIa studies. For this it plans to raise the required funds for taking up phase-IIa studies by going in for equity dilution. The valuations and milestone payments will be highly attractive if the results in phase-IIa studies are promising. If SUVN-502 is out-licensed now, it may get an upfront payment of some $30 million and if it out-licenses it after successful phase-IIa studies, it may get $130 million or so as upfront payment, (and) some $300 million over the period of trials and royalties in double-digit percentages once the drug hits the market.

This achievement is indeed commendable for a company the size of Suven especially since it is quite rare for even the biggest of pharma companies to discover a new chemical entity and that too for a difficult to treat disease like Alzheimer’s. It has already secured patents in nine countries including India for SUVN-502.

crack crack

Suven Life Sciences Share Price

191.00 -3.65 (-1.88%)

13-Apr-2026 11:28 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1653.60
Dr. Reddys Lab	1224.35
Cipla	1215.75
Zydus Lifesciences	929.30
Lupin	2329.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Suven Life Sciences plans to raise funds for clinical trials

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.